NNC 0151-0000-0000

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

HealthyInflammationRheumatoid ArthritisSystemic Lupus Erythematosus

Phase 1

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

WithdrawnNCT01018238

Novo Nordisk A/SInflammation, Systemic Lupus Erythematosus

Start: 2009-11-30End: 2009-11-30Updated: 2014-08-15

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

CompletedNCT02151409

Novo Nordisk A/SHealthy, Inflammation, Rheumatoid Arthritis +1

Start: 2008-06-30End: 2009-10-31Updated: 2017-02-09

Phase 2

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

CompletedNCT01223911

Novo Nordisk A/SInflammation, Rheumatoid Arthritis

Start: 2011-01-31End: 2013-02-28Updated: 2017-02-09